/주식/BDTX
BDTX

BDTX

USD

Black Diamond Therapeutics Inc. Common Stock

$1.590+0.000 (0.000%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$1.590

고가

$1.600

저가

$1.550

거래량

0.05M

기업 기본 정보

시가총액

91.2M

산업

생명공학

국가

United States

거래 통계

평균 거래량

3.25M

거래소

NMS

통화

USD

52주 범위

저가 $1.195현재가 $1.590고가 $7.66

AI 분석 리포트

마지막 업데이트: 2025년 4월 13일
AI 생성데이터 소스: Yahoo Finance, Bloomberg, SEC

[BDTX: Black Diamond Therapeutics Inc.]: News, Price Moves & What Investors Should Consider

Stock Symbol: BDTX Generate Date: 2025-04-13 20:27:17

Recent News Buzz: Good Vibes?

Things seem to be looking up for Black Diamond Therapeutics lately, at least if you read the news. The biggest headline is definitely the deal with Servier, a major pharmaceutical company. Basically, Servier is licensing one of Black Diamond's cancer drugs, BDTX-4933. This is a pretty big deal because it means Servier is putting its money and muscle behind developing and selling this drug globally. That's a strong vote of confidence in Black Diamond's science. Beyond that, Wall Street analysts at HC Wainwright and Stifel are both still saying "Buy" for the stock. One even raised their price target, though the other lowered theirs a bit. Even with the mixed price targets, the overall feeling from the news is definitely leaning positive. It suggests people who know the industry see potential in Black Diamond.

Price Check: What's Been Happening?

Let's peek at the stock chart. Over the last month or so, it's been a bit of a rollercoaster. If you look back to mid-January and February, the price was mostly drifting downwards, hitting lows around $1.80. Then, BAM! Around March 19th, the stock price shot up like a rocket. That jump almost certainly happened because of the Servier news. However, after that initial excitement, the price has come back down quite a bit. It's now hovering around $1.40. Interestingly, even though the price dropped after the news spike, it hasn't fallen back to its pre-news lows. It seems to have found a new, slightly higher level. Looking ahead, AI predictions suggest a tiny nudge upwards in the next few days, but nothing dramatic. So, the price action tells a story of initial struggle, a big positive event causing a surge, and then a settling period at a somewhat improved price point.

Putting It All Together: Potential Outlook & Strategy Ideas

So, what does all this mean for someone thinking about this stock? Well, the recent news is undeniably good. A major pharma partnership is a significant win for a smaller biotech company like Black Diamond. The "Buy" ratings from analysts, even with some price target adjustments, also add to the positive picture. The stock price chart shows a clear positive reaction to the news, even if that pop has faded a bit. Considering all of this, the situation might be leaning towards a potential buying opportunity, or at least a reason to keep a close watch.

If you were considering getting in, a possible entry point could be around the current price level, say in the $1.38 - $1.42 range. This area seems to be acting as a bit of a support level recently. Of course, things can always change. For managing risk, setting a stop-loss is always smart. Perhaps somewhere around $1.26 could be considered – that's a bit below recent lows and mentioned in some recommendations. On the upside, if things go well, a potential target to think about taking some profit might be around $1.57, based on recommendation data. Keep in mind, these are just potential levels to consider based on the data we have.

Ultimately, the news and price action suggest a potentially more stable or even slightly positive outlook for Black Diamond in the near term. However, like any stock, especially in biotech, it's not without risk.

Company Snapshot: Quick Context

Just a quick reminder: Black Diamond Therapeutics is a biotech company focused on cancer drugs. They're still in the clinical trial phase, meaning they're working on proving their drugs are safe and effective. This Servier deal is important because it helps validate their technology and brings in resources. They are a smaller company in the healthcare sector, so news like this can have a bigger impact on their stock compared to huge corporations.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. The stock market is inherently risky, and prices can fluctuate. Investors should conduct their own thorough research and/or consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.

관련 뉴스

GlobeNewswire

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential

더 보기
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $12

HC Wainwright & Co. analyst Robert Burns maintains Black Diamond Therapeutic with a Buy and raises the price target from $11 to $12.

더 보기
HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $12
Analyst Upgrades

Stifel Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $15

Stifel analyst Bradley Canino maintains Black Diamond Therapeutic with a Buy and lowers the price target from $16 to $15.

더 보기
Stifel Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $15

AI 예측Beta

AI 추천

강세

업데이트 시간: 2025년 4월 28일 오전 07:57

약세중립강세

59.0% 신뢰도

리스크 & 트레이딩

리스크 수준4/5
고위험
적합 대상
가치공격적
트레이딩 가이드

진입점

$1.57

익절

$1.78

손절

$1.43

핵심 요소

PDI 17.1이(가) ADX 9.3과 함께 MDI 14.5 위에 있어 강세 추세를 시사합니다.
현재 가격이 지지선($1.58)에 매우 근접하여 강력한 매수 기회를 시사합니다.
MACD 0.0017이(가) 신호선 0.0020 아래에 있어 약세 교차를 나타냅니다.

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기